Saturday, July 13, 2019 12:20:51 PM
Zafgen, Inc. (NASDAQ:ZFGN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy.
https://fintel.io/so/us/zfgn
Recent LRMR News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:09:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:06:02 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:57:52 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/14/2024 10:08:46 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 01:55:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 11:06:09 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 09:46:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 12:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:33:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:32:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:31:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:31:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:08:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 06:51:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 12:00:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:05:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:03:03 AM
- Larimar Therapeutics Shares Rise 10% After FDA Clears CTI-1601 Trial • Dow Jones News • 07/25/2023 05:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2023 11:02:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2023 08:15:06 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2023 08:13:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:08:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM